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Abstract 
 
A novel class of bivalent ligands targeting putative protease-activated receptor (PAR) heteromers has 
been prepared based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of 
the PAR1 antagonist RWJ-58259 containing alkyne adapters were connected via cycloaddition reactions 
to azide-capped polyethylene glycol (PEG) spacers attached to imidazopyridazine-based PAR2 
antagonists. Initial studies of the PAR1–PAR2 antagonists indicated that they inhibited G alpha q-
mediated calcium mobilization in endothelial and cancer cells driven by both PAR1 and PAR2 agonists. 
Compounds of this novel class hold promise for the prevention of restenosis, cancer cell metastasis, and 
other proliferative disorders. 
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Protease-activated receptors (PARs) are a unique family of class A G-protein-coupled receptors 
(GPCRs) that are activated by extracellular proteases, which reveal a tethered ligand at the N-
terminus.(1,2) Self-activation of PARs by their tethered ligand agonists leads to a wide range of cellular 
responses, in part due to the fact that PARs are highly expressed in different tissues with varying 
signaling components; they can also be activated by different proteases that cleave at different locations 
on the N-terminus.(3) The unusual complexity of PAR-mediated signaling is further increased by the 
potential for PARs and other GPCRs to form multireceptor complexes in cell membranes.(4) More 
specifically, evidence has emerged in recent years that PARs form homomeric and heteromeric 
complexes among the four different PAR subtypes, and the signals mediated by these complexes are 
distinct from those of the monomers.(5−7) Additionally, the N-terminus of one PAR subtype can directly 
activate a neighboring PAR.(8) 
The range of productive and pathological signaling for which PARs have been implicated has 
prompted their study as potential targets for numerous indications, including thrombosis, inflammation, 
stroke, kidney disease, reperfusion injury, and cancer cell metastasis (vide infra). Despite their 
therapeutic promise, to our knowledge only a few PAR modulators have thus far reached clinical stages, 
all as antithrombotic agents inhibiting platelet activation.(9−12) 
The present lack of clinical PAR modulators for other indications may reflect in part the 
pleiotropic signaling of PARs, which may complicate the selective inhibition of pathological signals 
without adversely affecting normal signaling. For example, PAR1 antagonists may prevent thrombosis 
via inhibition of PAR1 on platelets, while concurrently interfering with endothelial barrier integrity by 
inhibiting normal PAR1 signaling in endothelium. This has inspired our recent efforts to identify biased 
ligands that may inhibit or activate only a subset of PAR1-mediated signaling pathways.(13−15) 
An alternative therapeutic approach could utilize heterobivalent ligands to selectively target the 
differential signaling mediated by PAR heteromeric complexes (Figure 1). To our knowledge, no ligands 
selective for PAR heteromers have been reported. Evidence has been accumulating in recent years that 
GPCRs frequently form oligomers in vitro, but the in vivo relevance of these oligomers has been harder 
to quantify, in part due to a lack of adequate chemical tools.(4) The concept of bivalent ligands for 
multimeric GPCRs was pioneered by Portoghese nearly 40 years ago,(16) and this strategy has been used 
to generate compounds primarily for the study of CNS GPCRs.(17,18) Recently, promising in vivo data have 
been obtained that suggest that bivalent ligands can modulate GPCRs in a manner distinct from that of 
their monovalent counterparts.(19−22) This approach holds particular promise for PARs, as the differential 
tissue expression of PAR subtypes could permit tissue-selective targeting of PAR heteromers using 
heterobivalent ligands. This is best exemplified by the fact that PAR2 is not expressed on human 
platelets; therefore, we reasoned that PAR2-directed heterobivalent ligands could permit the selective 
modulation of signaling by PAR2-containing heteromers in vascular tissues without adversely affecting 
platelet activation and hemostasis. 
 
Figure 1. Proposed heterobivalent PAR ligands. 
Mueller and colleagues presented evidence that thrombin-enhanced migration of melanoma 
cells is driven by PAR1 and PAR2, in a manner consistent with the “direct transactivation” of PAR2 by 
thrombin-activated PAR1.(23) Bar-Shavit has also reported synergistic effects of PAR1 and PAR2 activation 
in tumor development(24,25) Kuliopulos reported that signaling by PAR1–PAR2 heteromers may be 
implicated in restenosis, the dangerous narrowing of blood vessels which occurs in a significant fraction 
of patients after percutaneous interventions (PCIs).(26) 
We hypothesize that heterobivalent antagonists may act selectively at putative PAR1–PAR2 
heteromers and thus may act to inhibit cancer cell metastasis and proliferative processes such as 
restenosis, while minimizing impacts on normal PAR signaling. PAR1 antagonists have been investigated 
for restenosis in animal models,(27,28) and individual PAR1(29,30) and PAR2 (31) antagonists have been 
studied in cancer cell metastasis and invasion. To our knowledge, however, none of these studies has 
progressed to clinical stages for these indications. One complication may arise from the fact that the 
tethered ligand of PAR1 can directly transactivate a neighboring PAR2 receptor, which could possibly 
happen even in the presence of a PAR1 antagonist.(8) Together, these observations make the 
preparation of multivalent PAR ligands an attractive strategy with benefits that may extend beyond the 
administration of multiple separate ligands. Herein we describe our initial efforts toward the synthesis 
and study of heterobivalent ligands targeting PAR1 and PAR2. 
The primary considerations for the design of heterobivalent ligands are as follows: 1. What 
monovalent ligands should be used? 2. What spacers should be used to connect them? 3. Where should 
the spacer be attached to each ligand? Based on its published SAR data and potential for diverse 
modifications, we elected to utilize the PAR1 antagonist RWJ-58259 as the first PAR1 scaffold for our 
bivalent ligands(27,32) and an imidazopyridazine scaffold reported by Vertex as the PAR2 antagonist.(33) To 
connect the ligands, we elected to first utilize commercially available polyethylene glycol (PEG)-based 
spacers with a variety of lengths, particularly for their beneficial physicochemical properties, especially 
increased water solubility. Also beneficial is the fact that bivalent ligands with PEG spacers with excess 
“slack” may pay less of an entropic penalty upon binding relative to those with more hydrophobic 
spacers,(34) presumably because hydrophilic PEGs can maintain flexibility in water and do not require 
highly ordered solvation shells. The use of commercially available amino-PEG-azide spacers permits 
convenient copper-catalyzed alkyne/azide cycloadditions (CuAAC), suitable for the connection of two 
appropriately functionalized ligands via the PEG spacer under diverse conditions.(35) We recently 
reported the synthesis of an alkyne-tethered version of RWJ-58259, which retained significant potency 
at PAR1.(15) Based on the SARs published for the imidazopyridazine reported by Vertex, we elected to 
prepare carboxyl-substituted versions of these PAR2 antagonists using the reported synthetic route 
(Scheme 1).(33) 3-Amino-6-chloropyridazine (1) was subjected to Suzuki coupling with 4-
fluorophenylboronic acid to yield the biarylamine 2. Bromination followed by alkylation with 
bromomethylpyruvate yielded the imidazopyridazine 4. Suzuki coupling with the propenylboronic ester 
A gave 5, and hydrogenation provided the ester 6. Hydrolysis followed by coupling with piperazine B 
yielded amide 8. Removal of the Boc group, coupling with succinic acid monomethyl ester, and 
hydrolysis of the resulting ester gave carboxylic acid 10a. PAR2 antagonists containing an arene 
substituent in place of the isopropyl group of 10a and a cyclohexyl carboxylic acid in place of the eastern 
ethylene group were among numerous analogs previously reported;(33) therefore, carboxylic 
acid 10b was additionally prepared (Scheme S1). Both of the carboxylic acids 10a and 10b were 
confirmed to be highly potent antagonists of PAR2 (vide infra), so we proceeded to couple them to a 
variety of PEG-based spacers (Schemes 2 and S2). Amide coupling with amino(PEG)azides, followed by 
CuAAC(36) with the previously synthesized RWJ-58259-based alkyne DG-207,(15) yielded heterobivalent 
ligands 13a–d. Control compounds 15–18 composed of the monovalent ligands with attached PEG 
spacers are depicted in Figure S1. 
 
Scheme 1. Synthesis of PAR2 Antagonist with Carboxylic Acid Adapter Based on Reported 
Imidazolopyridazines 
 
 
Scheme 2. Assembly of Heterobivalent PAR1–PAR2 Antagonists 
During the course of our studies, Marshall and colleagues reported several X-ray crystal 
structures of modified PAR2, including a cocrystal of PAR2 with the inhibitor AZ3451 at an allosteric site 
at the side of the receptor.(37) The structural similarities between 10a and AZ3451 led us to hypothesize 
that they may share a binding site on PAR2, which was supported by rigid protein docking studies 
(Figure 2a)(38) and is consistent with the allosteric mode of inhibition recently reported by Fairlie for the 
Vertex(33) imidazopyridazine I-191.(39) Compound 10a docks into the lipophilic pocket at the side of PAR2 
in a similar pose to AZ3451, with both molecules possessing a heterocyclic nitrogen capable of accepting 
a hydrogen bond from Tyr210. 
 
Figure 2. (A) X-ray structure of modified PAR2 with bound allosteric ligand AZ3451 (green) and docked 
ligand 10a (pink). (B) Novel bivalent ligand 20 and control compound 19 possessing a PEG-
aminoalkylamide spacer. 
The position of this binding site within the cell membrane suggests that the hydrophilic PEG 
spacer may be counterproductive and could explain the greatly decreased potency at PAR2 of our PEG-
linked PAR2 antagonists. We addressed this potential issue by synthesizing modified spacers containing 
a terminal aminoalkylamide that could possess a higher affinity for the cell membrane above the 
putative PAR2 binding site (Figure 2b and Scheme S3). 
The ligands were tested in our intracellular calcium mobilization assay (iCa2+) using the 
transformed human endothelial cell line EA.hy926, and this assay was also suitable for studying the 
signaling of the breast cancer cell line MDA-MB-231, which expresses both PAR1 and PAR2. Adherent 
cells were cultured in 96-well plates to confluence over ∼48 h, then loaded with the fluorescent calcium 
binding dye Fluo-4/AM, according to our reported protocol.(15) Addition of the antagonists, followed by 
the relevant PAR peptide agonists TFLLRN-NH2 (PAR1), SLIGKV-NH2(PAR2), or SFLLRN-NH2 (PAR1/2), 
permitted the measurement of inhibition of Gq-driven signaling from both PAR1 and PAR2. All 
concentration–response curves show data from N = 3 on a single plate, fitted using four-variable 
nonlinear regression with GraphPad Prism v. 5. Error bars represent standard error of the mean (SEM) 
for the three measurements at each concentration. 
The attachment of PEG spacers to the PAR1 antagonist RWJ-58259 and the PAR2 
antagonist 10awas tolerated, albeit with 5- to 70-fold decreases in potency. Half-maximal inhibitory 
concentration (IC50) for the inhibition of TFLLRN-NH2 (5 μM) PAR1-mediated iCa2+ mobilization increased 
from 0.02 to 0.1 μM for the PEG spacer-linked control 17 (Figure 3a). Compound 10a inhibited SLIGKV-
NH2 (5 μM) PAR2-mediated iCa2+ mobilization with an IC50 of 0.1 μM, and the PEG spacer-linked 
control 15 was significantly less potent (IC50 = 7 μM, Figure 3b). This is consistent with a report from 
Bunnett (published during revision of this manuscript) that describes an imidazopyridazine PAR2 
antagonist that suffers an approximately 1000-fold drop in potency upon attachment of a PEG tether at 
a similar site.(40) These compounds also showed good potencies in analogous assays with MDA-MB-231 
cancer cells (Figures 3c,d). 
 
Figure 3. Inhibition of TFLLRN-NH2 (5 μM) PAR1-mediated iCa2+ mobilization by monovalent PAR1 ligand 
RWJ-58259 and spacer-linked control 17 (A) in EA.hy926 endothelial cells and (C) in MDA-MB-231 cancer 
cells; inhibition of SLIGKV-NH2 (5 μM) PAR2-mediated iCa2+ mobilization by monovalent PAR2 
ligand 10a and spacer-linked control 15 (B) in EA.hy926 endothelial cells and (D) in MDA-MB-231 cancer 
cells. 
As described above, we proceeded to prepare bivalent ligands possessing spacers of different 
lengths, from shortest (21 atoms, 13a) to longest (72 atoms, 13d). To support their potential utility for 
future in vivo experiments, the stability of 13d was measured in mouse plasma, and a half-life of 5.6 h 
was determined (see Supporting Info for details). All four ligands showed good inhibition of PAR1-driven 
(TFLLRN-NH2) calcium mobilization in EA.hy926 cells, with comparable IC50s ranging from 0.03 to 0.18 
μM (Figure 4a). The efficacy of the longest ligand (13d) was higher than the others at the highest 
concentrations. All four ligands had much lower potency and efficacy as PAR2 antagonists, using SLIGKV-
NH2 as agonist (Figure 4b). An IC50 could only be estimated from the concentration–response curve 
fitted to the data from 13d, with an IC50 of 3.3 μM, and with only partial inhibition at the highest 
concentration (31.6 μM). The decreased potencies and efficacies of the bivalent ligands at PAR2, 
particularly comparing these ligands to the PEG-linked PAR2 antagonist controls, may reflect a higher 
affinity of the bivalent ligands for PAR1, and/or a higher receptor density for PAR1, such that ligands 
may be binding significantly to monomeric PAR1. 
 
Figure 4. Inhibition of TFLLRN-NH2 (5 μM) PAR1-mediated iCa2+ mobilization (A) and SLIGKV-NH2 (5 μM) 
PAR2-mediated iCa2+ mobilization (B) by bivalent ligands 13a–d in EA.hy926 endothelial cells. 
Next, the bivalent ligands 13a–d were tested for their ability to inhibit the PAR1/2 agonist 
SFLLRN-NH2, dosed at 3.16 μM (Figure 5a). Again, the ligand with the longest spacer (13d) proved to be 
most potent, with an IC50 of 0.15 μM. It was also compared to the control compounds composed of 
monovalent PAR1 (17) and PAR2 (15) ligands with spacers and their combination (Figure 5b). The 
combination of equal concentrations of 17 and 15 gave an IC50 of 0.32 μM, resulting in an inhibition 
profile very similar to that of the bivalent ligand 13d. The inability of the PAR2 ligand 15to inhibit 
SFLLRN-NH2 to any measurable degree suggests that its signaling is largely driven by PAR1 with EA.hy926 
cells. Inhibition with the bivalent ligands derived from the PAR2 ligand 10bwas inferior to those derived 
from 10a. These data are included in the Supporting Information(Figures S2–S4). 
 
Figure 5. Inhibition of SFLLRN-NH2 (3.16 μM) PAR1/2-mediated iCa2+ mobilization by bivalent 
ligands 13a–d (A) and individual and codosed monovalent control compounds (17 + 15) in EA.hy926 
endothelial cells (B). 
The bivalent ligand 13d was next studied in the breast cancer cell line with all three agonists 
(Figure 6). It was most effective at the inhibition of TFLLRN-NH2-driven calcium mobilization, with an 
IC50 of 0.14 μM and excellent efficacy. The IC50 for inhibition of SFLLRN-NH2 was 3.3 μM, with lower 
efficacy. The inhibition of SLIGKV-NH2 by 13d was less efficient, with an IC50 estimated at 3.5 μM, but 
with no inhibition observed at submicromolar concentrations. The bivalent ligand possessing a more 
hydrophobic spacer (20, Figure 2b) was also tested for its possible improved activity at PAR2; 
unfortunately, attachment of this spacer did not improve the inhibition of PAR2-mediated signaling 
(Figures S6–S8). 
 
Figure 6. Inhibition of TFLLRN-NH2 (5 μM) PAR1-mediated, SLIGKV-NH2 (5 μM) PAR2-mediated, and 
SFLLRN-NH2 (3.16 μM) PAR1/2-mediated iCa2+ mobilization of 13d in MDA-MB-231 breast cancer cells. 
Finally, 13d was tested for its ability to inhibit the natural PAR1- and PAR2-activating proteases 
thrombin (Figure S9) and trypsin (Figure S10). Compound 13d inhibited 1 nM thrombin with an IC50 of 
0.36 μM in Ea.hy926 cells, but interestingly, the spacer-linked control 17 was ∼10× more potent. The 
PAR2 antagonist 10a was a potent inhibitor of 5 nM trypsin (IC50 = 0.002 μM), but attachment of a 
spacer (15) abrograted its activity, and the bivalent ligand 13d also showed no inhibition of trypsin. 
We have reported the first examples of bivalent PAR1–PAR2 antagonists, and we demonstrated 
that the optimal compound 13d can perform similarly to the combination of monovalent control ligands 
in the inhibition of intracellular calcium mobilization in the transformed endothelial cell line EA.hy926, 
as well as the epithelial breast cancer cell line MDA-MB-231. However, the decrease in potency 
observed upon attachment of PEG-based spacers to the monovalent PAR1 and PAR2 ligands means that 
the ligands are less potent than the combination of monovalent ligands without spacers attached, 
though there is always a significant disadvantage of dosing multiple drugs to obtain a desired 
therapeutic effect. These considerations may be less important than the ability of a heterobivalent 
ligand to selectively inhibit a putative heteromeric receptor complex that drives a pathological effect, 
such as metastasis, without interfering with healthy cell signaling. We have not yet obtained evidence 
that the bivalent ligands disclosed here selectively inhibit putative PAR1–PAR2 complexes; an example 
of such evidence would be biphasic concentration–response curves, where the ligands inhibit a 
population of heteromers at lower concentrations. However, the ability to detect low concentrations of 
such complexes is limited by the precision of the calcium mobilization assay. Receptor binding assays 
with labeled ligands are planned that would be more suitable for the detection of low populations of 
heteromers, and studies on PAR-driven cancer cell migration are also underway. The main weakness of 
the present ligands is their decrease in potency at PAR2 upon attachment of spacers to the PAR2 
antagonist scaffolds, and therefore, we are presently investigating alternative PAR2 antagonists and 
spacers. Bivalent PAR1–PAR2 antagonists are a novel class of ligands that may hold promise for the 
inhibition of cancer cell metastasis, restenosis, and other proliferative diseases. 
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Boc tert-butoxycarbonyl 
CuAAc copper-catalyzed alkyne/azide cycloadditions 
DCE 1,2-dichloroethane 
DCM dichloromethane 
DIEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DPPF 1,1′-bis(diphenylphosphino)ferrocene 
EDC 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide 
GPCR G-protein coupled receptor 
HATU hexafluorophosphate azabenzotriazole tetramethyl uronium 
HOBt 1-hydroxybenzotriazole 
IC50 half-maximal inhibitory concentration 
iCa2+ intracellular calcium mobilization 
MI myocardial infarction 
PAR protease-activated receptor 
PCI percutaneous interventions 
PyBOP (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
SEM standard error of the mean 
TBTA tris(benzyltriazolylmethyl)amine 
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